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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, Taiwan S
BY-NC-ND license (http://creativecomWe investigated differences in outcomes between 68 children hospitalized with macrolide-
sensitive Mycoplasma pneumoniae pneumonia (MSMP group) and 25 children hospitalized with
macrolide-resistant M. pneumoniae pneumonia (MRMP group). In the MRMP group, 19 children
received macrolides and clinical failure occurred in six of which five had pneumonia progres-
sion during therapy.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Mycoplasma pneumoniae (MP) is a common cause of res-
piratory tract infections in school-aged children. Although
mild cases may resolve spontaneously without specific
treatment, targeted antibiotic therapy is required for moreof Microbiology, The Univer-




ociety of Microbiology. Published
mons.org/licenses/by-nc-nd/4.0/serious infections, especially those with pneumonia.1 Mac-
rolides, fluoroquinolones, and tetracyclines are therapeutic
options for MP infection, but only the macrolides have been
approved for use in young children.1,2 In the past decade,
macrolide-resistant M. pneumoniae (MRMP) have been
increasingly prevalent worldwide and rates of >50% have
been found in Japan and China.1,3 MRMP occurs because of
point mutation in the 23S rRNA with substitutions at the
2063 and 2064 positions associated with high-level resis-
tance.4 MRMP infections have been associated with persis-
tence of symptoms (fever and cough), slower reduction in
bacterial load, longer length of hospitalization, and moreby Elsevier Taiwan LLC. This is an open access article under the CC
).
128 K.-N. Cheong et al.frequent requirement for alternative therapy.1,5 Nonethe-
less, information on the relationship between macrolide
failure and disease progression remains limited.2,5 Here, we
studied this issue by a retrospective review of all pediatric
MP pneumonia in our hospital where the incidence of MRMP
was estimated to be approximately 30%.4Materials and methods
This study was conducted in a University-affiliated hospital
with 1650 beds. Pediatric patients (117 years) hospitalized
with pneumonia (according to clinical symptoms, chest ex-
amination, and radiological abnormalities) were included if
their respiratory tract specimenswere positive for MP by PCR
from January 2011 to March 2013. Microbiological in-
vestigations including blood culture and nasopharyngeal
aspirate (NPA) for common respiratory viruses (influenza A
and B, parainfluenza virus, adenovirus, and respiratory
syncytial virus) were routinely carried out.6 For older chil-
dren, sputum specimens were collected with standard pro-
cedures. Additional investigations including tests for
pneumococcal antigen (urine or pleural fluid) and PCR assays
for Streptococcus pneumoniae DNA (pleural fluid) were
conducted upon request.4,7 Request for MP nucleic acidTable 1 Patient characteristics
Characteristics M
No. of patients 6
Age (y) 8
Female 3












Radiological progression during macrolide 0
Outcome
Total fever (d) 8
Length of stay in hospital (d) 3
Change of macrolides to alternative therapyd 0
30-d mortality 0
a Including cardiovascular diseases (n Z 2) and Down’s syndrome (n
MRMP group.
b Three MSMP patients each with parainfluenza virus, respiratory sy
with sputum culture positive for Haemophilus influenzae. No patient
c Three patients in the MSMP group received azithromycin. The rem
MRMP group received clarithromycin.
d Percentages among children treated with macrolide.
Data are presented as n (%) or mean  SD.
MRMP Z macrolide-resistant Mycoplasma pneumoniae pneumonia; MS
applicable.detection was initiated by the frontline clinicians.2,4 Melting
curve analysis was used to identify MRMP mutations retro-
spectively for this study, as described previously.2,4 Patients
were categorized on the basis of the presence or absence of
23S rRNA gene mutations as MRMP and macrolide-sensitive
M. pneumoniae (MSMP), respectively. Clinical information
was retrospectively obtained from the patient’s record.
Antibiotics were administered according to standard dosages
includingmacrolides (azithromycin, 10mg/kg/d, once daily;
clarithromycin, 15 mg/kg/d, twice daily), tetracycline
(doxycycline, 4 mg/kg/d, twice daily), fluoroquinolones
(levofloxacin, 8 mg/kg/d, once daily) and b-lactams
(amoxicillin-clavulante, 4590 mg/kg/d, twice or thrice
daily, ceftriaxone, 5080 mg/kg/d, once or twice daily).
The patient demographics, disease course (oxygen require-
ment and intensive care admission), antibiotic treatment,
and outcome were compared between MSMP and MRMP pa-
tients. Pneumonia progression was defined by the worsening
of respiratory symptoms and increased radiological abnor-
malities. Macrolide failure was defined by pneumonia pro-
gression after at least 2 days of macrolide treatment. The
Chi-square or the Fisher’s exact test (2-tailed) was used for
categorical variables. Continuous variables were tested by
using the Student t test. The GraphPad software (San Diego,
CA, USA) was used for all statistical analyses.SMP group MRMP group p
8 25
.10  3.9 8.96  3.2 0.736
5 (51) 16 (64) 0.350
.0  2.3 7.5  2.4 0.912
(12) 1 (4) 0.436
(4) 1 (4)b > 0.99
(4) 1 (4) > 0.99
2 (47) 16 (64) 0.167
8 (70.5) 19 (76) 0.795
(1.4) 3 (12) 0.058
(0) 3 (12) 0.018
(4.4) 4 (16) 0.081
(1.5) 2 (8) 0.175
(0) 5 (26.3) 0.003
.1  2.8 9.8  3.7 0.039
.3  2.3 5.8  4.8 0.001
6 (31.6%) 0.001
(0) 0 (0) NA
Z 1) in the MSMP group and liver transplantation (n Z 1) in the
ncytial virus, and adenovirus respectively, and one MRMP patient
had pneumococcal coinfection.
aining 45 patients in the MSMP group and all 19 patients in the
MP Z macrolide-sensitive M. pneumoniae pneumonia; NA Z not
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During the study period, PCR for MP was carried out for 327
hospitalized children of which 101 (30.9%) were positive.
Eight patients were excluded because there was inade-
quate material for resistance genotype determination
(n Z 7) or incomplete clinical records (n Z 1). The
remaining 93 patients all had clinical findings indicative of
community-acquired pneumonia. Molecular testing of the
respiratory specimens revealed the presence of the A2063G
mutation in 25 patients (MRMP group), whereas the
remaining 68 patients had no mutations (MSMP group).
Table 1 showed that the total duration of fever and dura-
tion of hospitalization were both significantly longer in the
MRMP group than the MSMP group. Significantly more chil-
dren in the MRMP group than the MRSP group required a
change of macrolides to alternative therapy [doxycycline or
levofloxacin; 31.6% (6/19) vs. 0% (0/48), pZ 0.001]. In the
MRMP group, change to alternative therapy was required in
six children (Table S1 in supplementary data). Two patients
had single lobe consolidation (Patients 1 and 3) and four
patients had interstitial infiltrates (Patients 2 and 4e6) at
presentation. Clinical symptoms had persisted and wors-
ened in all six patients despite macrolide therapy for 36
days. In five children, subsequent chest radiographs
revealed deterioration of the radiological abnormalities.
Multi-lobar consolidation developed in three children (Pa-
tients 13, Fig. 1). One child developed pleural empyema
(Patient 1) and respiratory failure requiring admission to
the intensive care unit, ventilation support, and surgical
decortication. The remaining three children developed
alveolar infiltrates of a segmental nature. All children
recovered after switching to doxycycline (n Z 3),Figure 1. Radiological findings in three hospitalized children w
failure. (A) Patient 1, chest radiograph taken on Day 4 after onset
radiograph taken on Day 13 after onset, showing progression of con
radiograph taken on Day 7 after onset, showing bilateral interstitial
onset, showing progression with consolidation changes in right lung
Day 7 after onset, showing consolidation changes in right upper zon
showing progression of consolidation changes in right lung. MRMP Zlevofloxacin (n Z 1), or combination of doxycycline and
levofloxacin (n Z 2). A systemic steroid (intravenous
methylprednisolone) was given to one child (Patient 1,
Fig. 1) because of severe lung injury and slow response to
antimicrobial treatment.
Discussion
We described the therapeutic failure of macrolides in the
treatment of children hospitalized with MRMP pneumonia.
In the MRMP group, a rather high proportion (26.3%, 5/19)
of children had pneumonia progression after macrolide
failure. This is partly because our hospital is a referral
center and sicker children would be transferred from other
hospitals to us for further management. Delayed presen-
tation to our hospital after failing therapy as outpatients
and a long time lag before the institution of effective
therapy are other contributing factors (Table S1 in
supplementary data). Therefore, caution is required in the
interpretation of the proportion.
As in most other institutions, PCR for MP is not a routine
diagnostic test in our hospital.8 Tests are typically reques-
ted when there is a lack of response to standard treatment.
Therefore, there is often a time lag of several days to 1
week before laboratory confirmation of the etiological
diagnosis. Although several studies have described the
therapeutic efficacy of tetracyclines and fluroquinolones in
MRMP pneumonia,3,9 the empirical use of these agents for
pediatric pneumonia is a dilemma. Firstly, pneumonia
caused by MSMP and MRMP is clinically indistinguishable1
and there is currently no reliable way of predicting the
clinical course of MP pneumonia at presentation. Secondly,
tetracyclines and fluroquinolones have the potential forith MRMP pneumonia and disease progression after macrolide
, showing left middle zone consolidation. (B) Patient 1, chest
solidation changes and left side empyema. (C) Patient 2, chest
infiltrates. (D) Patient 2, chest radiograph taken on Day 12 after
and pleural effusion. (E) Patient 3, chest radiograph taken on
e. (F) Patient 3, chest radiograph taken on Day 10 after onset,
macrolide-resistant Mycoplasma pneumoniae pneumonia.
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cations, the use of these agents for initial treatment of
pediatric pneumonia is difficult.1 Current guidelines on
pediatric pneumonia recommend that children with clinical
features suspicious of MP be tested to guideline selection,
but graded it as a weak recommendation.8 Recent studies
have shown that molecular methods for identifying MP
nucleic acid in nasopharyngeal secretions can provide a
rapid and reliable diagnosis of MP infection. In our opinion,
improving timely access to such rapid tests would definitely
help to inform antibiotic selection. However, caution is
required in the interpretation of positive MP nucleic acid in
the upper respiratory tract because MP may be carried by
asymptomatic children and neither serology nor quantita-
tive PCR nor culture differentiated asymptomatic carriage
from infection.10
In conclusion, this study adds to a better understanding
of the consequence of macrolide failure in MRMP pneu-
monia. Vigilance is required because serious complications
can occur in some children within a few days after onset.
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